German biotechCureVacNV said on Wednesday itsCOVID-19vaccinewas only47%effective in a late-stagetrial, missing the study’s main goal and throwing in doubt the potential delivery of hundreds of millions of doses to the European Union.
The disappointingefficacyof the shot known as CVnCoV emerged from an interim analysis based on 134COVID-19cases in the study with about 40,000 volunteers in Europe and Latin America.
The stakes forCureVacand prospective buyers of itsvaccinein Europe had risen after age limits were imposed on the use of the Johnson & Johnson and AstraZenecavaccines due to a link to extremely rare but potentially fatal clotting disorders.
CureVac’s shot was al…
Keep on reading: CureVac fails in pivotal COVID-19 vaccine trial with 47% efficacy